Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas

Pharmacogenomics

Volumn 10, Issue 11, 2009, Pages 1781-1787

  Ragia, Georgia ^a   Petridis, Ioannis ^a,b   Tavridou, Anna ^a   Christakidis, Dimitrios ^b   Manolopoulos, Vangelis G ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Academic General Hospital Alexandroupolis   (Greece)

Author keywords

CYP2C9 polymorphism; Gliclazide; Glimepiride; Hypoglycemia; Sulfonylurea; Type 2 diabetes mellitus

Indexed keywords

CYTOCHROME P450 2C9; GLICLAZIDE; GLIMEPIRIDE; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; AGE; AGED; ALLELE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; GENETICS; MIDDLE AGED; RISK;

ADULT; AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RISK; SULFONYLUREA COMPOUNDS;

EID: 70649097093     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.96     Document Type: Article

References (26)

1. Amiel SA, Dixon T, Mann R, Jameson K: Hypoglycaemia in Type 2 diabetes. Diabet. Med. 25, 245-254 (2008). (Pubitemid 351322690)
2. Murata GH, Duckworth WC, Hoffman RM et al.: Hypoglycemia in Type 2 diabetes: a critical review. Biomed. Pharmacother. 58, 551-559 (2004).
3. Rendell M: The role of sulphonylureas in the management of Type 2 diabetes mellitus. Drugs 64, 1339-1358 (2004).
4. Burge MR, Schmitz-Fiorentino K, Fischette C, Qualls CR, Schade DS: A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in Type 2 diabetes mellitus. JAMA 279, 137-143 (1998). (Pubitemid 28068304)
5. Salas M, Caro JJ: Are hypoglycaemia and other adverse effects similar among sulphonylureas? Adverse Drug React. Toxicol. Rev. 21, 205-217 (2002). (Pubitemid 36018767)
6. Holstein A, Egberts EH: Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 111, 405-414 (2003). (Pubitemid 37486432)
7. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J: Effect of genetic polymorphisms in cytochrome p450 (CYP)2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet. 44, 1209-1225 (2005). ■■ Detailed review of the implication of CYP2C9 enzyme in the metabolism of oral antidiabetic drugs. (Pubitemid 41832564)
8. Becker ML, Visser LE, Trienekens PH et al.: Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in Type II diabetes mellitus. Clin. Pharmacol. Ther. 83, 288-292 (2008). ■ Pharmacokinetic study suggesting that carriers of CYP2C9 defective alleles require lower doses of sulfonylureas to regulate their serum glucose levels.
9. Suzuki K, Yanagawa T, Shibasaki T et al.: Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with Type 2 diabetes. Diabetes Res. Clin. Pract. 72, 148-154 (2006).
10. Niemi M, Cascorbi I, Timm R et al.: Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther. 72, 326-332 (2002). ■ Pharmacokinetic study showing the clinical significance of CYP2C9 null alleles genotyping in sulfonylurea treatment. (Pubitemid 35052992)
11. Wang R, Chen K, Wen SY, Li J, Wang SQ: Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin. Pharmacol. Ther. 78, 90-92 (2005). ■ Pharmacokinetic study showing that CYP2C9 polymorphisms may predict the optimal glimepiride dose in Type 2 diabetes mellitus patients.
12. Yin OQ, Tomlinson B, Chow MS: CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin. Pharmacol. Ther. 78, 370-377 (2005). ■ Pharmacokinetic study showing that CYP2C9 polymorphisms may predict the optimal glyburide dose in Type 2 diabetes mellitus patients. (Pubitemid 41393672)
13. Zhang Y, Si D, Chen X et al.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br. J. Clin. Pharmacol. 64, 67-74 (2007). (Pubitemid 46934414)
14. Manolopoulos VG: Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin. Chem. Lab. Med. 45, 801-814 (2007). ■ Comprehensive review of the most important gene polymorphisms with clinical value and their possible applications in drug prescribing.
15. Arvanitidis K, Ragia G, Iordanidou M et al.: Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam. Clin. Pharmacol. 21, 419-426 (2007). (Pubitemid 47084032)
16. Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257-1270 (2002).
17. Kirchheiner J, Bauer S, Meineke I et al.: Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 12, 101-109 (2002). ■ Pharmacokinetic study showing the effect of CYP2C9 polymorphisms on tolbutamide clearance and elimination half-life. (Pubitemid 34298914)
18. Holstein A, Plaschke A, Ptak M et al.: Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 60, 103-106 (2005). ■■ Seminal study introducing the association of CYP2C9 polymorphisms with severe hypoglycemia. (Pubitemid 40942788)
19. Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG: Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 10, 43-49 (2009).
20. American Diabetes Association Workgroup on Hypoglycemia: Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28, 1245-1249 (2005). ■ Clear and comprehensive set of instructions and criteria on how to define and report hypoglycemia.
21. Scheen AJ: Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 28, 601-631 (2005).
22. Kim YM, Yoo SH, Kang RY et al.: Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am. J. Health Syst. Pharm. 64, 166-175 (2007).
23. Siguret V, Pautas E, Gouin-Thibault I: Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam. Horm. 78, 247-264 (2008).
24. Elbekai RH, El-Kadi AO: Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol. Ther. 112, 564-587 (2006).
25. Yu BN, Luo CH, Wang D et al.: CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin. Chim. Acta 348, 57-61 (2004). (Pubitemid 39209001)
26. Diagnosis and Classification of Diabetes Mellitus: New Criteria www.aafp.org/afp/981015ap/mayfield.html